News about GILD

Gilead Sciences (NASDAQ: GILD) said on 19 October 2026 that its experimental oral ulcerative colitis pill, emvistegrast, met the main goal of the mid-stage SWIFT trial. At the 200mg dose, 66% of patients reached clinical response at Week 12 versus 37% on placebo, and 31% achieved clinical remission versus 8% on placebo. Despite the positive readout, GILD shares closed at $153.555, down 1.42%, on volume of 0.82 times the 20-day average, and RBC Capital Markets had said the data were unlikely to move the stock. The results follow a volatile quarter: Gilead posted a Q2 2026 net loss of $10,496m (EPS -$8.45) versus net income of $2,021m in Q1, though Q2 revenue rose to $7,803m from $6,960m. Gilead has not disclosed a timeline for advancing emvistegrast into late-stage testing.